Piramal Pharma Limited Assigned ESG Rating of 64 by NSE
Piramal Pharma Limited received an ESG Rating of 64 for FY 2024-25 from NSE Sustainability Ratings and Analytics. This marks an improvement from its previous score of 61, reflecting the company's commitment to sustainability.
An ESG rating is a general indicator of sustainability practices and does not have a direct, immediate financial impact on the company.
The ESG rating has improved, indicating positive progress in the company's sustainability efforts.
Piramal Pharma Limited (PPL) has been assigned an ESG Rating of 64 for FY 2024-25 by NSE Sustainability Ratings and Analytics Limited. This represents an improvement from the previous score of 61, underscoring the company's sustained commitment to responsible operations and sustainability initiatives.
The rating was received by the company on 6th April 2026. It is important to note that Piramal Pharma Limited did not engage NSE Sustainability for this rating; the report was prepared voluntarily by NSE Sustainability based on publicly available data from the company for the relevant fiscal year. The rating and related information are available on the NSE Sustainability Ratings & Analytics website, and the company has also uploaded this intimation on its corporate website at https://www.piramalpharma.com/.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.